In the general population, despite the ideal medications with angiotensin-converting enzyme inhibitors (ACEI), beta-blockers, and mineralocorticoid receptor antagonists (MRAs), the treatment for patients with heart failure remain unsatisfied due to hypotension, hyperkalemia, and renal function deterioration. Here, NR3C2 is linked to heart failure.